Old Web
English
Sign In
Acemap
>
authorDetail
>
Audrey Filézac de LÉtang
Audrey Filézac de LÉtang
Hoffmann-La Roche
Cancer research
Medicine
relapsed refractory
Polatuzumab vedotin
Diffuse large B-cell lymphoma
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
2021
Blood
Tycel Phillips
Michael Dickinson
Franck Morschhauser
Emmanuel Bachy
Michael Crump
Marek Trneny
Nancy L. Bartlett
Jan Maciej Zaucha
Kathryn Humphrey
David Perez Callejo
Linda Lundberg
James Relf
Audrey Filézac de LÉtang
David Carlile
Emma Clark
Carmelo Carlo-Stella
Show All
Source
Cite
Save
Citations (0)
Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2021
Blood
Martin Hutchings
Anna Sureda
María José Terol
Francesc Bosch Albareda
Paolo Corradini
Thomas Stauffer Larsen
Antonio Rueda Dominguez
Anesh Panchal
Alessia Bottos
David Carlile
Yanjie Wang
Audrey Filézac de LÉtang
Maneesh Tandon
Gila Sellam
Giuseppe Gritti
Show All
Source
Cite
Save
Citations (0)
1